MMSI

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is 100.57 USD with a low forecast of 90.00 USD and a high forecast of 109.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Merit Medical Systems Inc revenue for the last quarter amounts to 384.16M USD, increased 13.04 % YoY.

Merit Medical Systems Inc. EPS for the last quarter amounts to 0.46 USD, decreased -4.17 % YoY.

Merit Medical Systems Inc (MMSI) has 7400 emplpoyees as of December 15 2025.

Today MMSI has the market capitalization of 5.14B USD.